Insomnia and Cardiovascular Risk: The Cost of Hyperarousal

Insomnia and Cardiovascular Risk: The Cost of Hyperarousal

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief: Insomnia is best understood as a disorder of hyperarousal: the brain’s wake systems stay switched on when they should quiet. Sleep is the cardiovascular system’s main recovery shift, and hyperarousal keeps the system in daytime mode through the night. Prospective studies link insomnia to higher rates of hypertension, coronary disease, heart failure, stroke, and cardiovascular death, though these are associations rather than proven cause. Cognitive behavioral therapy for insomnia is the guideline-recommended first-line treatment because it targets the arousal itself and carries none of the cardiac risks of sleep medications. The watchword for this article: insomnia is not about losing sleep, it is about losing recovery.

Insomnia is a disorder of hyperarousal. The brain’s wake-promoting systems stay active when they should quiet down. The result is difficulty falling asleep, staying asleep, or sleeping restoratively, despite adequate time and opportunity to do so.

That distinction matters for the heart. Sleep is when the cardiovascular system shifts into recovery. During healthy sleep, sympathetic tone falls, blood pressure typically dips, heart rate slows, and stress hormones decline. The system moves from daytime activation toward parasympathetic restoration. In insomnia, that shift fails. Sympathetic activation persists, cortisol stays elevated, and blood pressure may not dip. The cardiovascular system stays in daytime mode during the hours meant for repair, and it does so night after night, year after year.

Prospective studies associate insomnia with higher risk of hypertension, coronary heart disease, heart failure, and stroke, and these associations generally persist after adjustment for traditional risk factors.(1, 2, 3) A 2019 meta-analysis found that certain insomnia symptoms predicted both all-cause and cardiovascular mortality.(4) Unlike many cardiovascular risk factors, insomnia is treatable, and the first-line treatment is behavioral rather than pharmacologic.

A Disorder of Hyperarousal, Not Just Lost Sleep

The dominant framework for insomnia is hyperarousal: the disorder reflects excessive activation of the body’s arousal systems, not simply a shortage of sleep drive.(5)

A useful way to picture it is to think of the cardiovascular system as running in two modes. Daytime mode is sympathetic-dominant, with higher blood pressure, faster heart rate, circulating stress hormones, and constricted vessels, all primed for action. Recovery mode is parasympathetic-dominant, with falling pressure, a slower heart rate, relaxed vessels, and active repair. Healthy sleep is when recovery mode runs. Roughly eight hours of recovery against sixteen hours of activity is the rhythm the system evolved for. Insomnia breaks that rhythm, because the sympathetic system never fully stands down.

One clinical observation captures the difference between hyperarousal and ordinary sleep loss. Many people with insomnia cannot nap during the day even when they feel exhausted.(5) If insomnia were simply a sleep deficit, daytime sleep would come easily. The inability to nap despite fatigue points to an aroused nervous system rather than a depleted one.

The Evidence for Hyperarousal

Several physiological signatures support this model. People with insomnia tend to secrete more cortisol over 24 hours than good sleepers, and the difference is most pronounced in the evening and overnight, when cortisol should be at its lowest.(6) Whole-body metabolic rate is elevated across both waking and sleep, consistent with persistent sympathetic activation.(7) Resting heart rate runs faster and heart rate variability runs lower, both markers of sympathetic dominance and reduced parasympathetic tone.(8) Neuroimaging adds a central correlate: brain regions that promote arousal show greater activity, and sleep-promoting regions show less, even during sleep itself.(9)

Taken together, these findings describe a nervous system that does not power down at night. That is the mechanism through which insomnia reaches the cardiovascular system.

Why Short Sleep Matters More

A recurring theme in this research is that not all insomnia looks the same biologically, and the evidence increasingly points to two distinct phenotypes.(21) In one, insomnia coexists with objectively normal sleep duration. The distress is real, and there is genuine cortical and emotional arousal, but the classic physiological stress markers are largely absent, and this version is not clearly tied to cardiometabolic harm.(21) In the other, insomnia comes with objectively short sleep, generally under six hours measured in the lab. This phenotype carries the fuller physiological signature, with activation of both the sympathetic and stress-hormone systems, and the degree of objective sleep disturbance tends to track the degree of that activation.(6, 21) It is also the version most consistently tied to hard outcomes, including hypertension, impaired heart rate variability, and higher mortality.(10, 21) The practical takeaway is that objectively short sleep may mark a biologically more severe form of the disorder. That is why the distinction keeps surfacing when insomnia is linked to blood pressure and cardiovascular risk.

What It Costs the Cardiovascular System

The cardiovascular toll of insomnia has been studied across several outcomes. A few points of interpretation apply throughout. These data are overwhelmingly observational, so they establish association rather than proof of cause, and residual confounding cannot be excluded. The figures below are mostly relative risks; the absolute increase for any one person depends on baseline risk and is usually more modest than the relative numbers suggest.

Hypertension shows the clearest signal when insomnia is paired with objectively short sleep. Studies suggest the association with high blood pressure is strongest in that subgroup.(10) Insomnia with short sleep reflects genuine sleep loss layered on hyperarousal, which compounds the cardiovascular burden.

For coronary heart disease, a meta-analysis of prospective studies found that insomnia was associated with roughly a 45 percent higher relative risk of developing or dying from cardiovascular disease (relative risk about 1.45).(1) The association held after adjustment for age, sex, and other risk factors, though again this is observational evidence.

Heart failure carries one of the larger reported associations. In the Norwegian HUNT study, people reporting all three insomnia symptoms had a markedly higher adjusted risk of incident heart failure than those with none, with a hazard ratio of 4.53.(2) The study followed more than 54,000 adults for an average of about 11 years, and roughly 1,400 developed heart failure. The absolute number of events stayed small even as the relative risk was high. Risk rose stepwise with the number of insomnia symptoms, which is the kind of dose-response pattern that strengthens, though does not prove, a causal interpretation.

Stroke and mortality round out the picture. Meta-analyses report associations between insomnia symptoms and incident stroke, with relative risk increases that are real but generally modest and vary by the specific symptom and population studied.(3, 22) For mortality, specific symptoms, particularly difficulty falling asleep and non-restorative sleep, were associated with higher all-cause and cardiovascular death, again most consistently when short sleep accompanied the insomnia.(4)

How Insomnia Reaches the Heart

The mechanisms follow directly from hyperarousal, and they continue to operate in people who already have cardiovascular disease, not only in those developing it.

The most direct pathway is sustained sympathetic activation. The arousal that defines insomnia keeps sympathetic tone elevated around the clock.(11) Blood pressure stays up when it should fall, heart rate stays quick when it should slow, and variability declines. Acute sympathetic activation is adaptive; chronic activation is corrosive.

A second pathway runs through the stress-hormone axis. Cortisol normally follows a daily rhythm, low at night, rising before waking, and tapering through the day. In insomnia that rhythm flattens, and evening and nighttime cortisol stay elevated when they should be at their nadir.(6) Persistently high nocturnal cortisol contributes to insulin resistance and glucose intolerance and has direct vascular effects, including endothelial dysfunction and impaired vascular repair.

Inflammation links the two. Insomnia is associated with chronic low-grade inflammation, reflected in markers such as CRP and IL-6.(12) This inflammatory signal is a plausible bridge between autonomic and hormonal dysregulation and the slow structural damage that accumulates in vessel walls over years.

Behavior amplifies all of the above. Sleep loss reshapes daily habits in ways that add cardiovascular load.(13) Fatigue cuts physical activity. Altered appetite signaling tends to nudge intake upward. Alcohol often gets used as a sleep aid even though it fragments sleep, and nicotine use can rise, each adding its own sympathetic push.

Drawing the section together, the chain from arousal to cardiovascular harm runs along a few consistent lines.

Treating It: CBT-I First

The first-line treatment for chronic insomnia is not a medication. It is cognitive behavioral therapy for insomnia. In the United States, it is recommended as the initial treatment by both the American College of Physicians and the American Academy of Sleep Medicine, and the European guideline reaches the same conclusion.(14, 15, 17)

The reasons matter for cardiovascular patients. CBT-I works on the underlying hyperarousal rather than masking it with sedation. Medications induce sleepiness; CBT-I retrains the brain’s sleep-wake regulation. That distinction is more than semantic, because the cardiovascular benefit of sleep depends on the autonomic shift toward parasympathetic dominance, the very shift that hyperarousal blocks and that sedation does not restore. The benefits also persist after treatment ends, with sustained improvement at 6 to 12 months in meta-analyses, whereas medication effects typically fade once the drug is stopped.(16) CBT-I also avoids the specific hazards that make sedatives awkward in cardiac patients. There are no interactions with cardiac drugs, no respiratory depression in those with sleep apnea, no orthostatic drops in heart failure, and no added fall risk in older adults.

None of this means medication has no place. The American Academy of Sleep Medicine maintains a separate guideline for the drug options, which are reasonable mainly for short-term use or when CBT-I is unavailable or insufficient.(23) What they do not do is resolve the underlying arousal, so they are best seen as a bridge rather than the destination.

The therapy targets the behaviors and thoughts that keep insomnia going.(17) Sleep restriction limits time in bed to match actual sleep, which raises sleep pressure and consolidates fragmented sleep. Stimulus control rebuilds the link between bed and sleep, replacing the conditioned association between bed and frustrated wakefulness. Cognitive work addresses the mental habits that feed arousal, such as catastrophizing about lost sleep, clock-watching, and straining to sleep. There is a self-defeating loop worth naming here: the harder a person tries to force sleep, the more arousal they generate, so the effort itself becomes part of the problem. Loosening that effort is one of the things cognitive work is for.

A natural question is whether treating insomnia lowers cardiovascular risk. The honest answer is that randomized trials with hard cardiovascular endpoints have not been done. What does exist is mechanistic: in trials of insomnia patients, CBT-I has lowered markers of inflammation after successful treatment.(18) Because inflammation is one of the bridges from insomnia to vascular disease, this is encouraging. But a change in a marker is not the same as a change in events, and that leap has not yet been demonstrated. Where in-person therapy is unavailable, digital CBT-I programs are an effective alternative.(19)

When Insomnia and Heart Disease Feed Each Other

Insomnia and cardiovascular disease reinforce each other, and the relationship is mechanistic in both directions rather than coincidental.

Cardiovascular disease causes insomnia through several concrete routes, with heart failure the clearest example.(20) Congestion produces orthopnea and paroxysmal nocturnal dyspnea, so patients wake short of breath when fluid shifts to the lungs on lying flat. Diuretics drive nocturia. Beta-blockers can disturb sleep architecture and cause vivid dreams. And the psychological weight of chronic disease, including anxiety and fear about the night, activates the same arousal systems that drive primary insomnia. Coronary disease and arrhythmia add their own disruptions, from nocturnal angina to palpitations to post-event hypervigilance.

Running the other way, the mechanisms already described do not switch off once disease is established. In a patient with coronary disease who also has insomnia, the insomnia is not a separate bookkeeping item. It is an active contributor, sustaining inflammation and sympathetic tone and denying the heart the recovery that sleep should provide.

A few practical implications follow. Optimize the cardiac condition first, because uncontrolled heart failure or unstable angina will disrupt sleep regardless of any behavioral work. Screen for sleep apnea, since comorbid insomnia and sleep apnea, sometimes called COMISA, is common, and a patient labeled with insomnia who actually has untreated apnea will not improve with CBT-I alone. Treat the insomnia with CBT-I, which is safe in cardiac patients. And give appropriate attention to mood and stress, which can perpetuate both insomnia and heart disease. Support here can come from clinicians as well as from family, clergy, or other trusted relationships, alongside the structured behavioral treatment.

Common Assumptions Measured Against the Physiology

The Bottom Line

The cardiovascular system needs recovery time, and sleep is the only extended window in the 24-hour cycle when sympathetic tone drops, blood pressure dips, and repair runs. Insomnia is not really about losing sleep — it is about losing recovery: the hyperarousal that defines it keeps the system in daytime mode around the clock, and that is what wears on the heart over years. The associations with hypertension, coronary disease, heart failure, stroke, and cardiovascular death are consistent and biologically coherent, but they are almost entirely observational, the absolute risk for any one person is usually modest, and the trial that would settle it — showing that treating insomnia prevents cardiac events — has not been done. So the honest claim is narrow: insomnia is a plausible and treatable contributor to cardiovascular risk, not a proven independent cause of heart attacks, which is enough to take seriously without overstating it. What makes it worth treating is that effective treatment exists and works on the disorder itself: CBT-I addresses the arousal directly, where medications only sedate around it.

What Comes Next

Article 6 turns from the disorder of staying awake to the problem of being awake at the wrong time. It examines circadian disruption, shift work, and jet lag, and the cardiovascular cost of asking the body to operate against its own clock.

Key Terms

Insomnia (chronic insomnia disorder): Persistent difficulty initiating or maintaining sleep, or non-restorative sleep, despite adequate opportunity, occurring at least three times a week for three months or more and causing daytime impairment.

Hyperarousal: A state of heightened physiological and cognitive activation, spanning elevated cortisol, metabolic rate, heart rate, and brain arousal activity, considered central to the pathophysiology of insomnia.

CBT-I (cognitive behavioral therapy for insomnia): A structured, non-pharmacologic, guideline-recommended first-line treatment that retrains sleep-wake regulation through behavioral and cognitive techniques.

Sleep restriction: A CBT-I component that limits time in bed to match actual sleep time, increasing homeostatic sleep pressure and consolidating sleep.

Stimulus control: A CBT-I component that rebuilds the learned association between the bed and sleep rather than wakefulness.

Nocturnal dipping: The normal overnight fall in blood pressure during healthy sleep; its loss reflects sustained autonomic activation.

HPA axis: The hypothalamic-pituitary-adrenal axis, the stress-hormone system that regulates cortisol release across the day.

COMISA: Comorbid insomnia and sleep apnea; common in cardiac patients, and a reason CBT-I alone may fail if coexisting apnea is untreated.

References

1. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol. 2014;21(1):57-64. doi:10.1177/2047487312460020. PMID: 22942213.
2. Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. Eur Heart J. 2014;35(21):1382-1393. doi:10.1093/eurheartj/eht019. PMID: 23462728.
3. Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol. 2014;176(3):1044-1047. doi:10.1016/j.ijcard.2014.07.284. PMID: 25156850.
4. Ge L, Guyatt G, Tian J, et al. Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: systematic review and meta-analysis of prospective cohort studies. Sleep Med Rev. 2019;48:101215. doi:10.1016/j.smrv.2019.101215. PMID: 31630016.
5. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14(1):19-31. doi:10.1016/j.smrv.2009.04.002. PMID: 19481481.
6. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab. 2001;86(8):3787-3794. doi:10.1210/jcem.86.8.7778. PMID: 11502812.
7. Bonnet MH, Arand DL. 24-hour metabolic rate in insomniacs and matched normal sleepers. Sleep. 1995;18(7):581-588. doi:10.1093/sleep/18.7.581. PMID: 8552929.
8. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med. 1998;60(5):610-615. doi:10.1097/00006842-199809000-00017. PMID: 9773766.
9. Nofzinger EA, Buysse DJ, Germain A, Price JC, Miewald JM, Kupfer DJ. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry. 2004;161(11):2126-2128. doi:10.1176/appi.ajp.161.11.2126.
10. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497. doi:10.1093/sleep/32.4.491. PMID: 19413143.
11. Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol. 2015;66:143-172. doi:10.1146/annurev-psych-010213-115205. PMID: 25061767.
12. Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry. 2016;80(1):40-52. doi:10.1016/j.biopsych.2015.05.014.
13. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci. 2008;1129:287-304. doi:10.1196/annals.1417.033. PMID: 18591489.
14. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. doi:10.7326/M15-2175. PMID: 27136449.
15. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700. doi:10.1111/jsr.12594. PMID: 28875581.
16. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(3):191-204. doi:10.7326/M14-2841. PMID: 26054060.
17. Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255-262. doi:10.5664/jcsm.8986. PMID: 33164742.
18. Irwin MR, Olmstead R, Carrillo C, et al. Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial. Sleep. 2014;37(9):1543-1552. doi:10.5665/sleep.4008. PMID: 25142571.
19. Zachariae R, Lyby MS, Ritterband LM, O’Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia: a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2016;30:1-10. doi:10.1016/j.smrv.2015.10.004. PMID: 26615572.
20. Redeker NS, Jeon S, Muench U, Campbell D, Walsleben J, Rapoport DM. Insomnia symptoms and daytime function in stable heart failure. Sleep. 2010;33(9):1210-1216. doi:10.1093/sleep/33.9.1210. PMID: 20857868.
21. Vgontzas AN, Fernandez-Mendoza J, Liao D, Bixler EO. Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder. Sleep Med Rev. 2013;17(4):241-254. doi:10.1016/j.smrv.2012.09.005. PMID: 23419741.
22. He Q, Zhang P, Li G, Dai H, Shi J. The association between insomnia symptoms and risk of cardio-cerebral vascular events: a meta-analysis of prospective cohort studies. Eur J Prev Cardiol. 2017;24(10):1071-1082. doi:10.1177/2047487317702043. PMID: 28359160.
23. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. doi:10.5664/jcsm.6470. PMID: 27998379.

HeartBuddi • Your heart. Own it.